Science at Sanofi

Catch up on EADV 2026 poster highlights: real-world dupilumab data in atopic dermatitis, bullous pemphigoid and prurigo nodularis. For healthcare professionals.

Explores the connections between Type 2 inflammatory diseases and the opportunities to improve patient outcomes through earlier, targeted intervention

Access ERS 2026 Congress highlights on severe asthma, COPD, and biologic therapies. Real-world evidence and clinical insights for HCPs

Explore ATS 2026 key sessions on dupilumab, COPD biologics, FeNO biomarkers, and asthma remission. Real-world evidence for HCPs

AAD 2026 post-congress: Complete systemic therapy update. Multi-indication clinical data for inflammatory dermatological conditions.

The United in Rare: Advancing LSDs Care across Asia event was held on the 22^nd to 23^rd November 2025 in Bangkok, Thailand. The event aimed to provide a platform for experts across Thailand, Malaysia, Singapore, Taiwan, South Korea and India to share their experiences in management of LSDs by discussing challenges cases and best practices to improve diagnosis and treatment pathways for LSDs.

The programme brought together international and local experts to discuss the evolving understanding of Type 2 inflammation in atopic dermatitis, with a focus on IL-4 and IL-13, disease modification, and the importance of early intervention across different patient populations. 

The United in Rare: Advancing LSDs Care across Asia event was held on the 22nd to 23rd November 2025 in Bangkok, Thailand. The event aimed to provide a platform for experts across Thailand, Malaysia, Singapore, Taiwan, South Korea and India to share their experiences in management of LSDs by discussing challenges cases and best practices to improve diagnosis and treatment pathways for LSDs.

Remission that holds after treatment stops is no longer a hypothetical. This edition opens with a review defining what disease modification in atopic dermatitis would actually require, then looks at what the evidence shows so far: sustained benefit in patients over 60, whether treating children early can change where the atopic march ends, and what happens to skin nerves and barrier proteins after 16 weeks of treatment.

DUPIXENT has demonstrated a consistent safety profile in adults with moderate-to- severe AD, supported by five years of clinical trial data and real-world evidence across all age groups from 6 months through adulthood.¹

Diagnostic uncertainty remains a common challenge in patients presenting with chronic respiratory symptoms. Watch this on-demand expert session featuring Prof Peter Wark as he discusses practical approaches to distinguishing asthma from COPD, recognizing overlapping features, and identifying patients who may benefit from early specialist referral. 

In this issue, we feature three studies that provide insights into disease modification in atopic dermatitis, examining microbiome restoration, long-term infection outcomes in real-world practice, and clinical responses in erythrodermic presentations.

Missed this webinar? You can now watch the recording of the webinar to learn about the role of biologics in severe asthma and COPD through real-world clinical cases presented by a panel of expert clinicians.

Curated evidence on atopic dermatitis, organised around the four disease-modification pillars — starting with new data on skin-barrier restoration in children.

Curated June evidence on atopic dermatitis, organised around the four disease-modification pillars — starting with new data on skin-barrier restoration in children